# Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer

> **NCT07634601** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 50 (estimated)

## Conditions studied

- Advanced Endometrial Carcinoma
- Metastatic Endometrial Carcinoma
- Recurrent Endometrial Carcinoma
- Stage III Endometrial Cancer
- Stage IV Endometrial Cancer

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **DRUG:** Elacestrant
- **DRUG:** Everolimus
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Positron Emission Tomography
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT07634601
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12-18
- **Primary completion:** 2028-12-18
- **Final completion:** 2029-12-18
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07634601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07634601, "Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07634601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*